Guangna Liu

This study shows that editing ULBP ligands reduces NK cell rejection of UCAR-T cells, improving their persistence and antitumor efficacy.

This paper reduces TCR mispairing in engineered T cells by disrupting disulfide bonds, improving safety without compromising cytotoxicity.

This paper develops dual-target CAR-γδT cells targeting B7-H3 and IL13Rα2 for glioblastoma therapy, showing superior tumor elimination compared to monospecific CAR-T constructs.